Posts Archive

MagnetisMM-5 Relapsed Refractory Multiple Myeloma NCT05020236: Phase 3 - MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and...

NCT05060627: An Open Label, Multicenter, Phase I/II Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed...

NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma A...

Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy NCT05090566: Phase 2: MagnetisMM-4: Umbrella Study of...

bb2121 Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (KarMMa-7) KarMMa-7 Relapsed & Refractory Multiple...

NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With...

NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma...

MagnetisMM-9 NCT05014412: Phase 1/2: A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That...

NCT04764942: Phase 1/2: Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With...

Pavurutamab NCT04998747: Phase 1: A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma...

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma...

NCT04973605: Phase 1/2: A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in...

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in...

NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple...

NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM) NCT04960579: Phase 1:...

NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma...

ClaSPd NCT04843579: Phase 2: Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed...

NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma This study will assess...

NCT04771078: Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial...